Interius BioTherapeutics is an early-stage biotechnology company focused on expanding the potential of cell and gene therapy by developing next generation delivery technology, based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.

Interius BioTherapeutics

Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.

BrightEdge Fund

OUP (Osage University Partners)

Penn Medicine

Penn Medicine Co-Investment Program

Pfizer Venture Investments

The Mark Foundation for Cancer Research

Quan Capital

RA Capital Management

Cormorant Asset Management

Agent Capital

Logos Capital

Team Interius ‘Turned It Red’ in recognition of Blood Cancer Awareness Month by hosting dinner for 60+ patients and caregivers at American Cancer Society's Hope Lodge in Philadelphia!

Because nothing says ‘comfort’ like a homecooked meal! 

From baked ziti and roasted chicken to brownies and a listening ear, our team showed up to serve!

It was a very rewarding experience for the Interians who participated and were able to visit with guests over dinner.

We are so very proud of our team and this initiative!

Summer 2024 took Interius to Citizens Bank Park!  

What a great time for the team to spend quality time together outside of work!  A great game and knock-out night spent cheering on The Phillies with friends & family!

Special shout out to Isabel Sampson-Mapp of the Netter Center for Community Partnerships at the University of Pennsylvania for connecting us with new friends from our West Phila community to share the game with and for facilitating so many opportunities throughout the year for Interius to be a good neighbor!

Go team Interius! And Go Phils!

Tyler Menichiello, thank you for the shoutout to our Senior Director of Analytical Development, Jim Richardson! Jim moderated a panel and Elaine Youngman presented at the 16th Annual Bioprocessing Summit, highlighting Interius BioTherapeutics' deep expertise in complex CMC and analytics matters in the advanced therapies field with an eye on cost, practical solutions, and interactions with regulators.

Glad to join the conversation at BioTechX USA these past couple of days in Philadelphia. Proud of the Interius BioTherapeutics team for sharing deep insights into IT systems, data capture, storage and architecture, and analytics workflows in support of rapid advancement of our therapeutic programs.

As we prepare for a big year-end, Team Interius took some time to kick back, relax, and enjoy the summer sun!

We hope everyone else is keeping it cool and groovy this summer too! ✌

An excellent article, which interviewed our CEO Philip R. Johnson, MD, describes Interius BioTherapeutics as "one of the most advanced companies in this space". Thank you, Nature Magazine and Asher Mullard for recognizing Interius's progress and unique approach to in vivo CAR T therapy. We look forward to clinical data emerging over the next year and bringing important advancements to the field.

Viewport Meta

IPhone / Mobile Compatible

Euro

Google Tag Manager

HSTS

Google Font API

Google Analytics

WordPress

Global Site Tag

Font Awesome

Senior Vice President of Operations, Chief of Staff

Dora Mitchell

Marketing and Product

Babu Medi, B.Pharm, Ph.D

Senior Director, Discovery

Bruce Schnepp

Senior Director, Analytical Development

Jim Richardson

Associate Director of Preclinical Biology

Leticia Kuri Cervantes

Business Management

Matt Troutman

Legal

Scott Dooley

Senior Director Upstream Downstream PD

Sianny Christanti

Laboratory Manager

Taylor Phillips

Operations

Ari Yasunaga

Carter Caldwell

Benjamin Lund

Tomas Kiselak

Saar Gill

Founder

Philip R. Johnson

Chief Executive Officer

Bruce A. Peacock

Co-Founder

Greater Philadelphia Area Companies (Top 10K)

United States Early Stage Companies (Top 10K)

Philadelphia Companies With More Than $1M in Revenue

Pennsylvania Startups Founded in 2019

Interius BioTherapeutics is a biopharmaceutical company that develops in vivo cell-specific gene medicines to treat B cell lymphomas. Intravenous in vivo CAR treatment, which treats B cell lymphomas, is the company's flagship program. Its unique engineering provides exceptional target tissue specificity. The business is working on a second initiative to address autoimmune conditions. With the help of Interius, a novel and distinct therapeutic modality for the precise administration of gene therapies may soon be made available to patients in expanded care settings, without the need for preconditioning chemotherapy.

Series B - Interius BioTherapeutics

Debt Financing - Interius BioTherapeutics

Fairmount Funds Management

Series A - Interius BioTherapeutics

Seed Round - Interius BioTherapeutics

Philadelphia

Pennsylvania

United States

North America

Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies

Interius BioTherapeutics receives approval for B-cell malignancy therapy trial

Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia

Interius’ INT-2104 receives Australian clearances for clinical trial in B-cell malignancies

Interius BioTherapeutics on LinkedIn: This morning Interius BioTherapeutics was honored to present our data…

Interius BioTherapeutics to Present In Vivo CAR Data in Oncology and Autoimmunity Programs at the American Society ...

Penn cell and gene therapy spinout Interius Biotherapeutics raises another $21.5M

A platform for delivering genes directly into specific cells within the body, focusing on generating CAR T cells in vivo for treating hematologic malignancies without ex vivo cell manipulation.

A lead program utilizing the company's gene delivery platform to create CAR T and NK cells in vivo for treating B-cell malignancies, demonstrated efficacy in preclinical models.

A collaboration for GMP manufacturing of INT-2104, leveraging WuXi ATU’s expertise for Phase I clinical product manufacturing.

Programs aimed at mentoring students and young scientists, including participation in 'Take Your Child to Work Day' and supporting the Philadelphia Science Olympiad.

Developer of CRISPR-based gene editing technologies for cellular engineering and analysis.

Caribou Biosciences

Biotechnology company focused on developing allogeneic CAR T therapies for cancer treatment.

Allogene Therapeutics

Developer of genome editing technologies and gene therapies for various genetic disorders and cancers.

Precision Biosciences

Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a breakthrough platform for targeted gene delivery. The company is focused on expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.

news impact assignment basic	general	Oct 2, 2024 10:59 AM	ae3bdec2
public peers	general	Oct 2, 2024 10:59 AM	8da2ece5
news daily refresh	general	Oct 2, 2024 10:59 AM	93c0f667
news processing daily refresh	general	Oct 2, 2024 10:59 AM	40bdd988
news impact assignment daily	general	Oct 2, 2024 10:59 AM	717f1051
news processing basic	general	Oct 2, 2024 10:59 AM	3e97f51c
company summary	general	Oct 2, 2024 10:59 AM	9b22183a
signals	general	Oct 2, 2024 10:59 AM	9494b270
crunchbase trigger	general	Nov 25, 2024 9:06 AM	d759b461
crunchbase profile	general	Nov 25, 2024 9:44 AM	824d6195
li profile	general	Oct 2, 2024 10:59 AM	a747d0bc
translate crunchbase fundingrounds	general	Nov 25, 2024 1:50 PM	2040b59c
peers	general	Oct 2, 2024 10:59 AM	00e6a12b
news basic	general	Oct 2, 2024 10:59 AM	6ba1193f
bundesanzeiger	filings	Oct 2, 2024 10:59 AM	f660ab64
financials download nd	financials
private financials	financials

COM:INTERIUSBIO

Interius BioTherapeutics